BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38165808)

  • 1. Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B.
    Hong J; Lee J; Park S; Jung HA; Sun JM; Lee SH; Ahn JS; Sinn DH; Ahn MJ
    Cancer; 2024 May; 130(9):1693-1701. PubMed ID: 38165808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis.
    Ding ZN; Meng GX; Xue JS; Yan LJ; Liu H; Yan YC; Chen ZQ; Hong JG; Wang DX; Dong ZR; Li T
    J Cancer Res Clin Oncol; 2023 May; 149(5):1993-2008. PubMed ID: 35767193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment.
    Yoo S; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Yoo C; Ryoo BY; Choi J
    Clin Gastroenterol Hepatol; 2022 Apr; 20(4):898-907. PubMed ID: 34182151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HBV reactivation and clinical resolution in an isolated anti-HBc-positive patient during immune checkpoint inhibition.
    Baumert LS; Shih AR; Chung RT
    Med; 2024 Feb; 5(2):126-131.e1. PubMed ID: 38340708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection.
    Megna M; Patruno C; Bongiorno MR; Gambardella A; Guarneri C; Romita P; Raimondo A; Loconsole F; Fabbrocini G
    Clin Drug Investig; 2022 Jun; 42(6):525-531. PubMed ID: 35633470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening.
    Elbedewy TA; Elashtokhy HE; Rabee ES; Kheder GE
    J Egypt Natl Canc Inst; 2015 Mar; 27(1):11-8. PubMed ID: 25716703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of HBV DNA and Hepatitis B Surface Antigen Levels With Tumor Response, Liver Function and Immunological Indicators in Liver Cancer Patients With HBV Infection Undergoing PD-1 Inhibition Combinational Therapy.
    Pan S; Yu Y; Wang S; Tu B; Shen Y; Qiu Q; Liu X; Su N; Zuo Y; Luan J; Zhang JY; Shi M; Meng F; Wang FS
    Front Immunol; 2022; 13():892618. PubMed ID: 35711409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients.
    Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Yang JC; Yu CJ
    Eur J Cancer; 2019 Aug; 117():107-115. PubMed ID: 31279301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence of occult hepatitis B in chronic hepatitis C patients treated with interferon-based antiviral therapy.
    Bal T; Onlen Y
    Arab J Gastroenterol; 2018 Mar; 19(1):33-36. PubMed ID: 29503077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection.
    Liu S; He Z; Wu W; Jin H; Cui Y
    Clin Rheumatol; 2023 Sep; 42(9):2369-2376. PubMed ID: 37219751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update.
    Hwang JP; Feld JJ; Hammond SP; Wang SH; Alston-Johnson DE; Cryer DR; Hershman DL; Loehrer AP; Sabichi AL; Symington BE; Terrault N; Wong ML; Somerfield MR; Artz AS
    J Clin Oncol; 2020 Nov; 38(31):3698-3715. PubMed ID: 32716741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevalence of viral hepatitis B markers among blood donors in the Republic of Guinea].
    Boumbaly S; Balde TAL; Semenov AV; Ostankova YV; Serikova EN; Naidenova EV; Valutite DE; Shchemelev AN; Zueva EB; Esaulenko EV; Totolian AA
    Vopr Virusol; 2022 Mar; 67(1):59-68. PubMed ID: 35293189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
    Chen FW; Coyle L; Jones BE; Pattullo V
    Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country.
    Murt A; Elverdi T; Eskazan AE; Salihoglu A; Ar MC; Ongoren S; Baslar Z; Soysal T
    Ann Hematol; 2020 Nov; 99(11):2671-2677. PubMed ID: 32737632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis.
    He MK; Peng C; Zhao Y; Liang RB; Lai ZC; Kan A; Li QJ; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M
    Cancer Immunol Immunother; 2021 Nov; 70(11):3207-3216. PubMed ID: 33813646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation.
    Yoo JJ; Cho EJ; Cho YY; Lee M; Lee DH; Cho Y; Lee JH; Yu SJ; Yoon SS; Yoon JH; Kim YJ
    Liver Int; 2015 Dec; 35(12):2530-6. PubMed ID: 26053357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B.
    Lee HL; Jang JW; Han JW; Lee SW; Bae SH; Choi JY; Han NI; Yoon SK; Kim HJ; Lee S; Cho SG; Min CK; Kim DW; Lee JW
    Dig Dis Sci; 2019 Oct; 64(10):2992-3000. PubMed ID: 30982209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of Hepatitis B Virus Reactivation and Hepatotoxicity in Patients Receiving Long-term Treatment With Tumor Necrosis Factor Antagonists.
    Pauly MP; Tucker LY; Szpakowski JL; Ready JB; Baer D; Hwang J; Lok AS
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1964-1973.e1. PubMed ID: 29702293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection.
    Yeh ML; Huang CF; Huang CI; Holmes JA; Hsieh MH; Tsai YS; Liang PC; Tsai PC; Hsieh MY; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Chung RT; Yu ML
    J Hepatol; 2020 Jul; 73(1):62-71. PubMed ID: 32061869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.